Published in Biomed Res Int on July 20, 2014
Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev (2016) 0.98
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy. Int J Mol Sci (2015) 0.84
Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma. Drug Des Devel Ther (2015) 0.81
Nanoparticles as potential new generation broad spectrum antimicrobial agents. Daru (2015) 0.80
Erythropoietin Pathway: A Potential Target for the Treatment of Depression. Int J Mol Sci (2016) 0.79
Elucidation of Exosome Migration across the Blood-Brain Barrier Model In Vitro. Cell Mol Bioeng (2016) 0.78
Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats. PLoS One (2016) 0.78
Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model. Mol Pharm (2016) 0.78
Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Deliv (2016) 0.77
Blood-brain barrier crossing and breakthroughs in glioblastoma therapy. Br J Clin Pharmacol (2016) 0.75
Plant Derived Phytocompound, Embelin in CNS Disorders: A Systematic Review. Front Pharmacol (2017) 0.75
Transendothelial Transport and Its Role in Therapeutics. Int Sch Res Notices (2014) 0.75
Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection. J Neuroimmune Pharmacol (2016) 0.75
Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective. Adv Pharm Bull (2016) 0.75
Targeted Nanotechnology in Glioblastoma Multiforme. Front Pharmacol (2017) 0.75
Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. Int J Mol Sci (2016) 0.75
Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther (2016) 0.75
Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril (2016) 0.75
Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord. Front Pharmacol (2017) 0.75
Exploring cellular uptake of iron oxide nanoparticles associated with rhodium citrate in breast cancer cells. Int J Nanomedicine (2017) 0.75
Avidin. Adv Protein Chem (1975) 10.27
Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release (2001) 4.81
Structure and design of polymeric surfactant-based drug delivery systems. J Control Release (2001) 3.48
Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage (2005) 3.17
Prodrugs: design and clinical applications. Nat Rev Drug Discov (2008) 3.16
Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev (2012) 2.98
Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release (2004) 2.92
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med (2009) 2.82
Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg (2006) 2.58
MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol (2005) 2.57
Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed Engl (2003) 2.37
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev (2002) 2.19
Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm (1999) 2.18
Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci (2010) 1.99
The role of the organ microenvironment in brain metastasis. Semin Cancer Biol (2010) 1.89
Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev (2001) 1.88
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev (2001) 1.62
Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm (2003) 1.61
Melittin-grafted HPMA-oligolysine based copolymers for gene delivery. Biomaterials (2012) 1.61
Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm (2007) 1.60
The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. ScientificWorldJournal (2009) 1.58
Delivery of therapeutic proteins. J Pharm Sci (2010) 1.58
Interaction of immunoglobulins with liposomes. J Clin Invest (1974) 1.58
Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine (2011) 1.58
Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res (2007) 1.54
Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens. J Invest Dermatol (2012) 1.53
Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol (2010) 1.51
Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials (2010) 1.49
Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst (2002) 1.46
Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol (2004) 1.45
Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes. J Control Release (2014) 1.44
Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res (2013) 1.42
Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res (1998) 1.37
CNS drug design based on principles of blood-brain barrier transport. J Neurochem (1998) 1.37
Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew Chem Int Ed Engl (2004) 1.36
Molecular imprinting within hydrogels. Adv Drug Deliv Rev (2002) 1.36
Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control (2004) 1.34
Lipidic systems for in vivo siRNA delivery. AAPS J (2009) 1.33
Microchips as Controlled Drug-Delivery Devices. Angew Chem Int Ed Engl (2000) 1.31
Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol (2009) 1.27
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev (2003) 1.25
Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol (2004) 1.25
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J (2008) 1.24
Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine (2007) 1.21
Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A (2013) 1.19
Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci U S A (1999) 1.19
Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. Front Biosci (2007) 1.18
Prodrug approaches for CNS delivery. AAPS J (2008) 1.17
Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv (2010) 1.17
Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today (2000) 1.17
A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci U S A (1994) 1.14
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev (2013) 1.13
Adenosine 5'-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res (2003) 1.12
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (2009) 1.12
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev (2013) 1.12
Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol (2010) 1.12
Pharmacology of neurotrophic factors. Annu Rev Pharmacol Toxicol (1997) 1.12
Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res (2010) 1.11
Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) (2012) 1.11
Influence of microbubble surface charge on capillary transit and myocardial contrast enhancement. J Am Coll Cardiol (2002) 1.11
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res (2013) 1.10
GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.10
Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie (2006) 1.10
SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials (2013) 1.09
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad Sci U S A (2012) 1.08
Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Ther (2013) 1.07
Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks. J Clin Invest (2013) 1.07
Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat Commun (2013) 1.06
HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic Biol Med (2010) 1.06
Virus-derived siRNAs and piRNAs in immunity and pathogenesis. Curr Opin Virol (2011) 1.06
Peptide/protein hybrid materials: enhanced control of structure and improved performance through conjugation of biological and synthetic polymers. Macromol Biosci (2004) 1.05
Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Stroke (2013) 1.05
A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat Struct Mol Biol (2013) 1.04
Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier. J Agric Food Chem (2010) 1.04
Barriers to non-viral vector-mediated gene delivery in the nervous system. Pharm Res (2011) 1.04
Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One (2013) 1.04
Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One (2010) 1.04
Intranasal drug delivery for brain targeting. Curr Drug Deliv (2005) 1.04
Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int J Mol Sci (2013) 1.03
Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther (2002) 1.03
The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv (2012) 1.03
Preparation and in-vitro Evaluation of an Antisense-containing Cationic Liposome against Non-small Cell Lung Cancer: a Comparative Preparation Study. Iran J Pharm Res (2013) 1.02
Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci (2004) 1.02
Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res (1999) 1.02
Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm (2004) 1.01
The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol (2002) 1.00
Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling. Expert Opin Drug Metab Toxicol (2012) 1.00
Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J Control Release (2008) 1.00
Highly water-soluble, porous, and biocompatible boron nitrides for anticancer drug delivery. ACS Nano (2014) 0.99
Drug delivery to brain tumors. Curr Neurol Neurosci Rep (2008) 0.98
Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury. J Neurotrauma (2011) 0.98
Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm (2009) 0.97
Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res (1997) 0.97
Quaternary ammonium beta-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecules (2009) 0.97
Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids (2015) 0.95